David A. Siegel Macrogenics Inc Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Macrogenics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 857,100 shares of MGNX stock, worth $1.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

857,100

Previous 1,068,200 19.76%

Holding current value

$1.46 Million

Previous $1.36 Million 23.53%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.06 - $1.79 $223,766 - $377,869	-211,100 Reduced 19.76%	857,100 $1.04 Million
Q1 2025 May 15, 2025	SELL	$1.26 - $3.49 $63,504 - $175,896	-50,400 Reduced 4.51%	1,068,200 $1.36 Million
Q4 2024 Feb 14, 2025	BUY	$3.18 - $4.46 $237,215 - $332,698	74,596 Added 7.15%	1,118,600 $3.64 Million
Q3 2024 Nov 14, 2024	SELL	$3.0 - $5.55 $322,188 - $596,047	-107,396 Reduced 9.33%	1,044,004 $3.43 Million
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $3.81 Million - $21.3 Million	1,151,400 New	1,151,400 $4.89 Million
Q3 2023 Nov 14, 2023	SELL	$4.48 - $6.19 $2.13 Million - $2.95 Million	-476,200 Reduced 83.53%	93,900 $437,000
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $1.87 Million - $3.05 Million	-404,900 Reduced 41.53%	570,100 $3.05 Million
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $786,624 - $1.18 Million	-163,200 Reduced 14.34%	975,000 $6.99 Million
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $639,610 - $1.34 Million	191,500 Added 20.23%	1,138,200 $7.64 Million
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $221,234 - $383,670	-73,500 Reduced 7.2%	946,700 $3.28 Million
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $1.74 Million - $7.73 Million	774,100 Added 314.55%	1,020,200 $3.01 Million
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $1.73 Million - $3.6 Million	212,900 Added 641.27%	246,100 $2.17 Million
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $287,971 - $396,028	18,100 Added 119.87%	33,200 $533,000
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $2.69 Million - $3.92 Million	-136,500 Reduced 90.04%	15,100 $316,000
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $1.9 Million - $3.31 Million	-92,900 Reduced 38.0%	151,600 $4.07 Million
Q1 2021 May 17, 2021	SELL	$18.99 - $33.2 $1.53 Million - $2.67 Million	-80,500 Reduced 24.77%	244,500 $7.79 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $2.33 Million - $3.11 Million	119,800 Added 58.38%	325,000 $7.43 Million
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $93,822 - $120,080	-3,800 Reduced 1.82%	205,200 $5.17 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $4,680 - $26,208	900 Added 0.43%	209,000 $5.84 Million
Q1 2020 May 15, 2020	BUY	$4.28 - $12.11 $55,640 - $157,430	13,000 Added 6.66%	208,100 $1.21 Million
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $1.55 Million - $2.39 Million	195,100 New	195,100 $2.12 Million
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $220,188 - $309,396	-17,700 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $256,827 - $348,867	17,700 New	17,700 $300,000
Q3 2018 Nov 14, 2018	SELL	$19.26 - $23.46 $217,638 - $265,098	-11,300 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$19.78 - $24.67 $223,514 - $278,771	11,300 New	11,300 $233,000

Others Institutions Holding MGNX

# of Institutions

119

Shares Held

52.3M

Call Options Held

55.3K

Put Options Held

35.9K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $104M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account